Search results
Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst F
Guru Focus· 35 minutes agoAkero Therapeutics Inc (AKRO, Financial) released its 8-K filing on May 10, 2024, detailing its financial results for the first quarter of 2024. The clinical-stage biotechnology company, focused ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 28 minutes agoBragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Exscientia plc. (NASDAQ ...
Madrigal sees ‘tremendous interest’ in NASH drug Rezdiffra
Seeking Alpha· 5 days agoMadrigal Pharmaceuticals (MDGL) reports encouraging initial uptake for its newly approved liver ...
FROM THE GUT: 'Fatty liver' gets a name change and a close look
The Fredericksburg Free Lance-Star· 17 hours agoBack then, “Friends” was a top TV show, Michael Jordan was winning championships and politics was...
AKRO Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class...
Morningstar· 2 days agoRobbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Akero Therapeutics, Inc. (NASDAQ: AKRO) securities ...
AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC...
FOX21 Colorado Springs· 2 days agoKahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C....
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 6 days agoNew York, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie ...
Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Re
Guru Focus· 6 days agoMadrigal Pharmaceuticals, a clinical-stage biopharmaceutical entity, is at the forefront of addressing cardiovascular-metabolic diseases and non-alcoholic steatohepatitis ...
Contact Hagens Berman by June 25, 2024 Deadline to Join Class Action Against Akero Therapeutics...
Morningstar· 3 days agoSAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who suffered substantial losses to take action by submitting your losses ...
AKRO Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges Akero Therapeutics, Inc. Investors...
Morningstar· 1 day agoThe law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern ...